SCHEMBL6490344

SCHEMBL6490344

Nc1ccc(-c2cc3c(N)n[nH]c3cc2Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.57
GSK3B P49841 1/20 0.57
JAK2 O60674 2/20 0.54
JAK1 P23458 1/20 0.54
TYK2 P29597 1/20 0.54
JAK3 P52333 1/20 0.54
PRKAB2 O43741 14/20 0.52
PRKAG1 P54619 14/20 0.52
PRKAA2 P54646 14/20 0.52
PRKAA1 Q13131 14/20 0.52
PRKAG3 Q9UGI9 14/20 0.52
PRKAG2 Q9UGJ0 14/20 0.52
PRKAB1 Q9Y478 14/20 0.52
KIT P10721 1/20 0.50
KDR P35968 1/20 0.50
FLT3 P36888 1/20 0.50
PDPK1 O15530 1/20 0.46
HAVCR2 Q8TDQ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479455 0.88 CYP1A2 (0.56) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL6477985 0.88 GSK3B (0.56) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL6490982 0.88 GSK3B (0.55) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL3361082 0.87 JAK2 (0.57) GSK3BJAK2JAK1TYK2JAK3
SCHEMBL6488817 0.86 PDPK1 (0.58) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL27623401 0.85 PRKAB2 (0.57) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL6479588 0.84 GSK3B (0.61) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL6487188 0.79 GSK3B (0.57) CYP1A2GSK3BJAK2JAK1TYK2
SCHEMBL6478270 0.77 GSK3B (0.63) GSK3BJAK2JAK1TYK2JAK3
SCHEMBL1461596 0.74 GSK3B (1.00) CYP1A2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101962365-A Aminoindazole derivatives as protein-kinase inhibitors AVENTIS PHARMA SA 2011-02-02 CN claimed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US claimed
CN-1656078-A Aminoindazole derivatives as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2005-08-17 CN claimed
EP-1487804-B1 AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2014-02-26 EP disclosed
CN-101962365-A Aminoindazole derivatives as protein-kinase inhibitors AVENTIS PHARMA SA 2011-02-02 CN disclosed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US disclosed
CN-1656078-A Aminoindazole derivatives as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2005-08-17 CN disclosed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof CYP2C8, NR0B2, NR2C2 CYP1A2 49/4885GSK3B 2342/4885JAK2 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.